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Abstract
Purpose To determine the medium-term outcomes for patients with advanced glaucoma undergoing viscocanalostomy.
Methods All patients with advanced glaucoma (mean deviation (MD) − 12.00 dB or above) and patients with poor visual acuity
secondary to advanced glaucomawhich precluded formal visual field assessment undergoing viscocanalostomy (VC) and phaco-
viscocanalostomy between 2010 and 2014 under the care of a single surgical team were included. Intraocular pressure (IOP),
visual acuity (VA) and visual field outcomes were assessed from data prospectively collected into a surgical outcome database.
Success was defined at two IOP cut-off points: IOP ≤ 21 and ≤ 16 mmHg with (qualified) or without (complete) medications.
Results One hundred thirty-five patients were included. Mean IOP changed from 23.6 ± 6.4 mmHg pre-operatively to 15.3, 15.8
and 14.8 mmHg at 1, 2 and 3 years, a change of 35, 33.5 and 39% respectively. Qualified success for an IOP ≤ 21 mmHg was
achieved in 95.66, 90.6 and 80% and complete success in 52.5, 48.6 and 30.6% at year 1, 2 and 3. Qualified success for an IOP ≤
16mmHgwas achieved in 66.6, 66.05 and 60% and complete success in 44.8, 37.6 and 30.6% at year 1, 2 and 3. The cumulative
probability for achieving an IOP ≤ 21 mmHg with or without drops was 86.1, 81.4 and 81.4% at 12, 24 and 36 months. Eleven
patients (8.1%) failed to achieve adequate IOP control and needed further surgical intervention. Eleven (8.1%) patients needed an
intervention (Yag goniopuncture) following VC. Four patients (2.9%) had some post-operative complications, which resolved
within 2 weeks following surgery. Nine patients (6.7%) lost more than 2 Snellen lines. There was no significant change in theMD
across time points.
Conclusion Viscocanalostomy and viscocanalostomy combined with phacoemulsification is a safe and effective method of
controlling IOP in the medium term in patients with advanced glaucoma.
Keywords Viscocanalostomy . Phaco-viscocanalostomy . Advanced glaucoma . Non-penetrating glaucoma surgery . Glaucoma
Introduction
Patients most at risk of blindness during their lifetime, due to
glaucoma, are those who present with advanced disease.
Almost 60% of patients progressing to statutory blindness
have one eye with an MD worse than − 14 dB at baseline
[1]. Ten to thirty-nine percent of glaucoma patients present
with advanced disease in at least one eye in the UK [2–4].
The preferred option for most glaucoma and non-glaucoma
specialists in the UK is to start with primary medical therapy,
citing surgical risk as the primary reason behind it (23 and
22% respectively) [5].
National Institute for Health and Clinical Excellence
(NICE) guidelines recommend primary surgery for patients
presenting with advanced disease [6]. However, there is lim-
ited evidence supporting this recommendation and the type of
surgery to be offered.
Stead and King [7] have reported medium-term results for
trabeculectomy combined with mitomycin C (MMC) in pa-
tients with advanced glaucoma (MD ≤ 20 dB). Although
trabeculectomy was successful at controlling intraocular pres-
sure (IOP) in this group, a quarter of patients experienced a
significant reduction in acuity, with the pre-operative MD cit-
ed as the only determinant for it.
The treatment for advanced glaucoma study (TAGS) will
report the outcomes of primary trabeculectomy augmented
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withMMC compared with medical management for advanced
glaucoma [8]. Non-penetrating glaucoma surgery (NPGS) has
been shown to provide comparable long-term qualified suc-
cess rates to trabeculectomy, with reduced post-operative
complications [9–11] but there is limited information on its
success in patients with advanced glaucoma.
In this study, we assessed the outcomes of viscocanalostomy
(VC) and phaco-viscocanalostomy (phaco-VC) in patients with
advanced glaucoma to document success in terms of IOP and
VA and the post-operative interventions undertaken to achieve
these.
Methods
Advanced glaucoma was classified as MD between − 12.00 and
− 20.00 dB and severe glaucomaMD − 20.01 dB or worse [12].
All patients with advanced glaucoma and patients with
poor VA secondary to advanced glaucoma which precluded
formal visual field (VF) assessment undergoing VC and
phaco-VC between 2010 and 2014 under the care of a single
surgical team were included.
The technique involved superior corneal traction with 7-0
vicryl. A fornix-based conjunctival flap was raised superiorly
and haemostasis was achieved using wet field cautery. A two-
third scleral thickness limbus-based flap (5 × 5 mm) was
raised and advanced 1 mm into clear cornea. A 4 × 4-mm deep
scleral flap was dissected to the level of Schlemm’s canal
(SC), de-roofing it, and extended into corneal stroma to the
level of Descemet’s membrane to create the trabeculo-
Descemet’s membrane (TDM). Viscoat™ (sodium
hyaluronate and sodium chondroitin sulphate) was injected
into the two surgically created ostia of SC, aiming at dilating
both the ostia and the canal, and was also placed in the scleral
bed. The deep flap was excised close to the TDW. The super-
ficial scleral flap and conjunctiva were closed tightly with 10-
0 vicryl sutures. The formation of a bleb was not intended. No
antimetabolite was used.
There were no specific exclusion criteria. Data on all pa-
tients were included until the last recorded appointment,
which was considered the end of their follow-up. Post-
operative time points analysed were day 1, week 1, month 3,
month 6 and then every 6 months or closest to that point.
Minimum follow-up was 1 year. An intervention was defined
as any procedure or process undertaken after VC aimed at
enhancing the success of the surgical outcome. This was
Nd:YAG laser goniopuncture (Yag GP).
Primary outcomes were changes in IOP and visual field
(MD). These were assessed from data prospectively collected
into a surgical outcome database. Secondary outcomes were
change in VA, post-operative complications and interventions
and number of glaucoma drops (Drops) used.
Subgroup analysis was performed to look at confounding
factors such as age, race, combined cataract surgery and pre-
vious glaucoma surgery or laser. Differences in outcomes be-
tween primary open-angle glaucoma (POAG) and secondary
glaucoma were also examined.
SPSS v22 (SPSS, Chicago, IL) was used to perform statis-
tical analysis. Normality of data (IOP, Drops and visual field
MD) was examined using the Kolmogorov-Smirnov test. A
linear mixed model was used to examine for differences in
IOP and MD between pre-operative (pre-op) and year 1
(Y1), year 2 (Y2), year 3 (Y3) post-operatively and to com-
pare the two MD groups at these time points. Drops were
examined with Friedman’s test and if a difference was found,
pairwise comparisons were conducted using the Wilcoxon
test. Associations between presenting IOP, cataract surgery
post-VC and combined phaco-VC were examined with point
biserial correlation.
Success definition
Success was defined at two IOP cut-off points (IOP ≤
21 mmHg and IOP ≤ 16 mmHg). Complete surgical success
was IOP ≤ 21 or ≤ 16 mmHg with no additional medications
and qualified surgical success with additional glaucoma med-
ications. Failure was defined as IOP > 21 mmHg on two con-
secutive visits, IOP ≤ 5 mmHg on two consecutive visits after
3 months, reoperation for glaucoma or loss of light perception.
VA was measured on a Snellen chart, and a reduction of ≥ 2
lines was considered clinically significant.
Results
One hundred thirty-five eyes of 133 patients were included in
the study. Patient demographics for all variables over time can
be seen in Table 1. Sixty-three (46.7%) patients had phaco-
VC. The majority of eyes (132) were on topical glaucoma
drops pre-operatively. IOP at diagnosis was not known in 55
patients, as these were referred from other units, and this in-
formation was not provided. Twenty-five patients had had
some previous intervention for glaucoma including
trabeculectomy, cyclodiode laser, argon laser trabeculoplasty
(ALT) and selective laser trabeculoplasty (SLT) (Table 1).
IOP outcome
IOP was significantly lower at all examined time points (Y1
by 35.0%; Y2 by 33.5%; Y3 by 39.2%, p < 0.001 at all time
points) compared to the pre-op value. Glaucoma drops were
significantly different across time points (p = 0.001) with a
significantly lower median at all examined time points com-
pared to pre-op. Visual field MD was not significantly differ-
ent across time points (p = 0.289). When comparing IOP,
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Drops and MD scores between the two MD groups, no signif-
icant interaction was seen between groups and time points for
IOP (p = 0.999), Drops (p = 0.384) or MD (p = 0.061).
Descriptive statistics of all of the above can be seen in Table
2, while Fig. 1 displays IOP and Drops data plotted over the
time points.
Qualified success for an IOP ≤ 21 mmHg was achieved in
95.66, 90.6 and 80% and complete success in 52.5, 48.6 and
30.6% at year 1, 2 and 3. Qualified success for an IOP ≤
16 mmHg was achieved in 66.6, 66.05 and 60% and complete
success in 44.8, 37.6 and 30.6% at year 1, 2 and 3 (Table 3).
Eleven patients (8%) failed (4 in Y1, 4 in Y2 and 3 in Y3)
to reach any of the above success criteria and needed further
surgical intervention (Table 4). Of these, four had uveitic glau-
coma, two were pseudoexfoliative glaucoma (PXFG) and five
were POAG.
Kaplan-Meier survival curves were significantly different
between complete and qualified success with IOP ≤ 21 (p =
0.001, Fig. 2) but not between different glaucoma types
(complete (p = 0.912) and qualified (p = 0.541)) or between
MD groups (complete (p = 0.512) and qualified (p = 0.079)).
Visual acuity outcome
VAwas stable for the vast majority of patients (126 patients,
93.3%). Nine patients lost > 2 Snellen lines. This was from
glaucoma and high myopia in seven and proliferative diabetic
retinopathy in two patients. Majority of these patients (eight
out of nine) had MDworse than − 20 dB. In two patients with
MD < − 20 dB, VA dropped significantly from 6/36 at pre-op
to hand movement and perception of light in the early post-
operative period (presumed wipe out).
Visual field changes
One hundred fifteen patients were able to perform a reliable
VF (24-2 Humphrey’s visual field) prior to surgery. The num-
ber of patients that were able to perform a reliable VF
Table 1 Patient demographics
N (%) Mean SD Median Range
Age (years) 135 (100) 69.8 13.9 73 25 to 92
Duration of glaucoma (years) 101 (74.8) 10.8 7.1 10 1 to 30
Race
Caucasian 125 (92.6)
African/Afro-Caribbean 4 (3)
Asian 6 (4.4)
Presenting intraocular pressure (mm Hg) 78 (57.8) 32.7 12.0 29 17 to 64
Pre-operative intraocular pressure (mm Hg) 135 (100) 23.6 6.4 22 14 to 44
Pre-operative visual acuity 111 (82.2) 6/6–6/9 6/6–6/9 to hand
movement
Pre-operative drops (number) 135 (100) 3.1 1.1 3 0 to 5
Pre-operative MD (dB) 115 (85.2) − 19.6 5.5 − 19.4 − 12 to − 32.7
Previous procedures
None 110 (81.4)
Trabeculectomy 11 (8.1)
Retinal detachment surgery 7 (5.2)
SLT, ALT 4 (3.0)
Cyclodiode 3 (2.2)
Glaucoma type
Primary open-angle glaucoma 92 (68.1)
Chronic angle closure glaucoma 11 (8.1)
Pseudoexfoliation 10 (7.4)
Uveitic 8 (5.9)
Pigment dispersion 6 (4.4)
Normal tension glaucoma 5 (3.7)
Fuchs’ heterochromic cyclitis 3 (2.2)
Patient numbers (and as percentage of whole sample), mean ± SD or median and range (minimum to maximum values), as appropriate, are presented for
each variable
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gradually decreased over the follow-up period. Fifty-two pa-
tients were able to complete a reliable VF by final follow-up.
In these patients, MD was not significantly different across
time points (p = 0.105) compared to pre-op as a group and
for individual patients.
Confounding factors
Presenting IOP, age, glaucoma type and glaucoma duration and
having previous surgery did not comprise a sufficiently good
model that could predict the intervention (Yag GP, p = 0.128) or
intra- and post-operative complications following surgery (p =
0.175). There was no significant difference noted in the out-
come between VC and phaco-VC (p = 0.313). All descriptive
statistics of the above variables can be found in Table 1.
Cataract surgery
Three (5%) out of the 59 patients, who underwent VC and
were phakic at the time of surgery, underwent cataract surgery
by their final follow-up. Twenty-three (17%) were
pseudophakic pre-viscocanalostomy.
Complications
Four patients (2.9%) had some post-operative complication
following VC, which resolved within 2 weeks and did not
cause any visual loss (Table 5).
Post-operative intervention
Eleven (8.1%) patients needed Yag GP following their opera-
tion. The time frame for this varied between 2 and 18 months.
Discussion
We report our results with un-augmented VC in a cohort of
patients with advanced glaucoma. VC was able to achieve an
IOP ≤ 21mmHg in 80 (3 years) to 95% (1 year) patients with a
35–39% drop in IOP from baseline with a good safety profile.
To our knowledge, our study provides the largest number of
eyes with the longest follow-up yet reported for VC in patients
with advanced glaucoma.
There is limited evidence for the outcomes of glaucoma
surgery for advanced glaucoma and no recent studies
reporting the outcomes of NPGS for this cohort of patients.
Ates et al. [13], in 1999, reported their experience of deep
sclerectomy with collagen implant in 54 eyes with ad-
vanced glaucoma with 96.2% patients maintaining an
IOP < 18 mmHg over 2 years. In our cohort, IOP reduction
was maintained significantly below pre-operation levels up
to 3 years after surgery. We have previously reported qual-
ified (87.5–90.2%) and complete success (78–90%) rates
in a cohort of patients with POAG [10]. Shaarawy et al.
[11] have previously reported a 90% qualified and 60%
complete success rate at 5 years with VC. It is likely that
Schlemm’s canal sclerosis and collapse with advanced dis-
ease is the most likely explanation for the lower complete
Table 2 Descriptive statistics of
IOP, Drops and MD at all time
points including number of
patients per year
Pre-op (135) Y1 (135) Y2 (109) Y3 (75)
IOP (mm Hg) 23.6 ± 6.4 15.3 ± 3.2* 15.8 ± 4.1* 14.8 ± 3.4*
For MD between − 12.01 and − 20.00 dB 22.1 ± 5.2 15.3 ± 3.1 15.9 ± 3.3 15.0 ± 2.7
For MD − 20.01 dB and worse 23.9 ± 6.5 15.5 ± 3.6 15.2 ± 3.1 14.8 ± 3.8
Drops (number of) 3, 0–5 0, 0–3* 1, 0–4* 1, 0–4*
Mean deviation (dB) − 19.6 ± 5.5 − 18.8 ± 5.6 − 18.0 ± 10.5 − 19.8 ± 4.4
IOP and MD data is presented as mean ± SD, while Drops data as median and range. Asterisk denotes significant
difference with pre-op
IOP intraocular pressure, Drops number of medications,MDmean deviation, Y1 year 1 post-operation, Y2 year 2
post-operation, Y3 year 3 post-operation
Fig. 1 Mean intraocular pressure (IOP) and median number of drops
(Drops) plotted against the time points. Error bars have been excluded
for clarity. Asterisk denotes significant difference with pre-operative
values. Pre-op, pre-operative; M6, month 6 post-operative (not consid-
ered in statistical analysis); Y1, year 1 post-operation; Y2, year 2 post-
operation; Y3, year 3 post-operation
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success rates for VC in the present study. We have previ-
ously augmented VC with MMC in high-risk eyes [9] but
did not find a difference in outcome when compared to un-
augmented VC [9, 10], which suggests a possible bleb-
independent mechanism for the success of VC.
Trabeculectomy is still considered the gold standard and
achieves better control of IOP than VC [14]. The benefits
of NPGS however are potential gains for the patient in
terms of their quality of life and reduced likelihood for
post-operative interventions and sight-threatening compli-
cations [14]. Kirwan et al. [15] in a recent multicenter
analysis of current trabeculectomy practice reported the
requirement for frequent post-operative interventions in
the majority of patients concluding that completion of
trabeculectomy is just the beginning of a process that takes
several months to complete.
There are no like-for-like trials and limited published data
to compare our results to those for trabeculectomy or NPGS in
a similar patient cohort. Stead and King’s [7] results for
trabeculectomy augmented with MMC in advanced glaucoma
fare better in terms of IOP control compared to our group.
However, with regard to post-operative interventions, 79.8%
patients had some form of bleb manipulation [7] compared to
only 8.1% in our study that had Yag GP.
Reduced VA is a well-recognised complication of glau-
coma surgery and might be due to glaucoma progression,
comorbidity or the procedure itself. Kirwan et al. [15] re-
ported the outcomes of 428 trabeculectomies. Fifteen per-
cent had lost > 1 Snellen line at 1 year and 6% had lost > 2
Snellen lines by 2 years post-trabeculectomy (13% with
advanced visual field loss). Twenty-seven percent of pa-
tients in Stead and King’s study experienced a loss of two
or more lines of Snellen acuity [7]. Nine patients (6.7%) in
our study experienced a loss of > 2 Snellen lines. Eight of
these nine patients had a MD worse than 20 dB. The drop in
vision was attributed to glaucomatous progression in seven
eyes (5.2%), two (1.5%) of which were presumed to be a
wipe out. The risk of loss of central vision in patients with
advanced VF loss ranges from rare to as high as 14% [16,
17]. This may be attributable to readily identifiable compli-
cations including cataract, cystoid macular edema,
suprachoroidal and vitreous haemorrhage, endophthalmitis
and uveitis or be unexplained (wipe out). The exact mech-
anism of the Bwipe out^ phenomenon remains elusive, but
has been linked to sudden intra-operative hypotony
resulting in optic nerve haemorrhage and decreased perfu-
sion pressure to an already compromised nerve [18]. The
lower rates of drop in vision in the present study reflect the
benefit of avoiding sudden decompression with VC in eyes
with end-stage glaucoma.
Cataract formation is a reported complication after
trabeculectomy and can be in the order of 78% [19]. More
Table 4 Details of failures
No
Type of
glaucoma
Previous
surgery/laser
Pre-op IOP
(mmHg)
Pre-op MD
(dB)
Pre-op
BCVA
Pre-op drops
(No)
BCVA at
final
follow-up
MD (dB)
at final
follow-up
Time of
failure post-op
(months)
1 FHC Nil 20 U/C 6/60 3 6/60 U/C 24
2 FHC Nil 32 − 18.59 6/12 3 6/18 − 21.54 36
3 POAG Nil 28 − 25.7 6/6 1 6/9 − 29.23 36
4 PXFG Nil 39 − 27.48 6/36 5 6/36 U/C 24
5 POAG Previous VC 30 − 12.87 6/6 4 6/9 − 14.85 24
6 FHC Nil 28 − 23.92 6/12 4 6/18 − 25.48 24
7 POAG Nil 24 − 21.73 6/6 4 6/9 − 22.68 12
8 POAG Nil 24 U/C 6/60 4 6/60 U/C 24
9 Uveitic
glaucoma
Cyclodiode 28 − 14.73 6/24 4 6/36 − 16.73 24
10 POAG Nil 25 − 16.73 6/6 4 6/6 − 17.75 12
11 PXFG Trabeculectomy 16 − 21.07 6/12 4 6/12 − 22.78 24
U/C unable to perform reliable fields, POAG primary open-angle glaucoma, FHC Fuchs’ heterochromic cyclitis, PXFG pseudoexfoliation glaucoma
Table 3 Complete and qualified
success for IOP ≤ 16 mmHg and
IOP ≤ 21 mmHg (number and
percentage)
Y1 Y2 Y3
IOP ≤ 16 mmHg with no medication 60/135 (44.8%) 41/109 (37.6%) 23/75 (30.6%)
IOP ≤ 16 mmHg with additional medication 90/135(66.6%) 72/109 (66.05%) 45/75 (60.0%)
IOP ≤ 21 mmHg with no medication 71/135 (52.5%) 53/109 (48.6%) 23/75 (30.6%)
IOP ≤ 21 mmHg with additional medication 129/135(95.66%) 96/109 (90.6%) 60/75 (80%)
IOP intraocular pressure, Y1 year 1 post-operation, Y2 year 2 post-operation, Y3 year 3 post-operation
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recent data suggest this to be in the order of 30% [15]. King et
al. [7] reported a 63% incidence of cataract requiring surgery
in 27% cases. In comparison, only 5% patients in our group
required cataract surgery in the study period. Cataract surgery
can decrease the success of a trabeculectomy with an in-
creased likelihood of post-operative interventions and require-
ment for glaucoma medication in 30–39% cases [20, 21].
These risks are avoided with VC due to its bleb-independent
mechanism of action.
NICE recommends primary surgery should be offered to
patients presenting with advanced loss [6]. Stead and King
recommend this to be trabeculectomy augmented with
MMC [7]. The use of antimetabolites is a recognised risk
factor for bleb-related infection and endophthalmitis [22]
and reflects the opinion of UKConsultants’ for not advocating
primary surgery for this group [2]. Avoidance of antimetabo-
lite use and bleb-related complications with VC is an impor-
tant consideration in this group of patients. An advantage of
VC is retention of the TDW, which appears to serve as a
barrier to infection [22] and allows titrated aqueous flow, thus
avoiding hypotony and its complications.
NPGS techniques have greater safety with a lower risk of
complications when compared to trabeculectomy [22–25]. A
Cochrane review reported relatively fewer complications with
NPGS (17%) compared to trabeculectomy (65%) [14]. The
UK national trabeculectomy surgery survey [26] reported ear-
ly complications in 46.6% and late complications in 42.3%
cases. Only four patients (2.9%) had some post-operative
complication in our study, which resolvedwithin 2 weeks with
no long-term complications.
Visual field MD was not significantly different across
time points (p = 0.105) compared to pre-op in our study.
However, the number of patients completing a VF declined
year on year, with 45.2% of patients finally completing a
reliable VF. This may be expected with time [1] and is
comparable to previous reports where only 39% of patients
with advanced glaucoma were able to complete a reliable
VF at 1 year, 35% at 3 years and 17% at 5 years post-
trabeculectomy [7, 27].
Of the 11 eyes that failed, 4 had uveitic glaucoma (3 Fuchs’
heterochromic cyclitis (FHC)) and 2 PXFG) both known to
have an aggressive course [28]. We have previously reported
good outcomes for NPGS in uveitic glaucoma [10]. In this
study, eight patients had uveitic glaucoma of which three
had FHC, all of which failed. This could be related to the
increased likelihood of subclinical neovascularisation and
Schlemm’s canal sclerosis in FHC [29].
Limitations of this study include the loss of numbers,
particularly those able to complete a reliable VF test during
the follow-up period. However, to our knowledge, this is
the first study to report the effectiveness of un-augmented
VC for advanced glaucoma. IOP remained controlled over
a period of up to 3 years, albeit with the requirement of
increasing medications with time and VA remained stable
in the majority of patients. VC had similar qualified suc-
cess rate to MMC trabeculectomy with a good safety pro-
file, avoidance of MMC and its attendant complications
and minimal post-operative interventions. The benefits
can also be extrapolated to the wider context of economic
and quality of life benefits to be achieved with NPGS [30].
NICE recommends primary surgery in this group of pa-
tients [6]. TAGS will address the outcomes of primary
trabeculectomy with MMC for advanced glaucoma [8].
Our study supports the extension of the trial to include
the use of primary VC for advanced glaucoma.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee and with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards.
Fig. 2 Kaplan-Meier survival plot for complete (defined as IOP ≤
21 mmHg with no medication) and qualified (defined as IOP ≤
21 mmHg with additional glaucoma medications) success
Table 5 Intra- and post-operative complications
Complication type No. of patients
Intra-op TDW* perforation 17/135
Wound conjunctival leak treated
with bandage contact lens
2/135
Scleral flap leak repaired with tutoplast 1/135
Wound leak repaired with suturing 1/135
*Trabeculo-Descemet’s window
1486 Graefes Arch Clin Exp Ophthalmol (2018) 256:1481–1487
Informed consent This was a retrospective study. For this type of study,
formal consent is not required.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP
(2014) Examining visual field loss in patients in glaucoma clinics
during their predicted remaining lifetime. Invest Ophthalmol Vis
Sci 55:102–109
2. Ng WS, Agarwal PK, Sidiki S, McKay L, Townend J, Azuara-
Blanco A (2010) The effect of socio-economic deprivation on se-
verity of glaucoma at presentation. Br J Ophthalmol 94:85–87
3. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO,
Yawn BP, Butterfield LC, Gray DT (1998) The probability of blind-
ness from open-angle glaucoma. Ophthalmology 105:2099–2104
4. Coffey M, Reidy A, Wormald R, Xian WX, Wright L, Courtney P
(1993) Prevalence of glaucoma in the west of Ireland. Br J
Ophthalmol 77:17–21
5. King AJ, Stead RE, Rotchford AP (2011) Treating patients present-
ing with advanced glaucoma should we reconsider current practice?
Attitudes of consultant ophthalmologists in the UK to initial man-
agement of glaucoma patients presenting with severe visual field
loss: a national survey. Clin Exp Ophthalmol 39:858–864
6. NICE Guideline NG81 (2017) Glaucoma: diagnosis and manage-
ment. https://www.nice.org.uk/guidance/ng81. Accessed 14 March
2018
7. King AJ, Stead RE (2011) Outcome of trabeculectomy with mito-
mycin C in patients with advanced glaucoma. Br J Ophthalmol 95:
960–965
8. King AJ, Fernie G, Azuara-Blanco A, Burr JM, Garway-Heath T,
Sparrow JM, Vale L, Hudson J, MacLennan G, McDonald A,
Barton K, Norrie J (2017) Treatment of Advanced Glaucoma
Study: a multicentre randomised controlled trial comparing primary
medical treatment with primary trabeculectomy for people with
newly diagnosed advanced glaucoma-study protocol. Br J
Ophthalmol. https://doi.org/10.1136/bjophthalmol-2017-310902
9. Choudhary A, Wishart PK (2007) Non-penetrating glaucoma sur-
gery augmented with mitomycin C or 5-fluorouracil in eyes at high
risk of failure of filtration surgery: long-term results. Clin Exp
Ophthalmol 35:340–347
10. Wishart PK, Wishart MS, Choudhary A, Grierson I (2008) Long-
term results of viscocanalostomy in pseudoexfoliative and primary
open angle glaucoma. Clin Exp Ophthalmol 36:148–155
11. Shaarawy T, Nguyen C, Schnyder C, Mermoud A (2003) Five year
results of viscocanalostomy. Br J Ophthalmol 87:441–445
12. Mills RP, Budenz DL, Lee PP, Noecker RJ, Walt JG, Siegartel LR,
Evans SJ, Doyle JJ (2006) Categorizing the stage of glaucoma from
pre-diagnosis to end-stage disease. Am J Ophthalmol 141:24–30
13. Ates H, Andac K, Uretmen O (1999) Non-penetrating deep
sclerectomy and collagen implant surgery in glaucoma patients
with advanced field loss. Int Ophthalmol 123:123–128
14. Eldaly MA, Bunce C, Elsheikha OZ, Wormald R (2014) Non-
penetrating filtration surgery versus trabeculectomy for open-
angle glaucoma. Cochrane Database Syst Rev (2):CD007059.
https://doi.org/10.1002/14651858.CD007059.pub2.Review
15. Kirwan JF, LockwoodAJ, Shah P,MacleodA, BroadwayDC, King
AJ, Mcnaught AI, Agrawal P, Trabeculectomy Outcomes Group
Audit Study Group (2013) Trabeculectomy in the 21st century: a
multicenter analysis. Ophthalmology 120:2532–2539
16. Topouzis F, Tranos P, Koskosas A, Pappas T, Anastasopoulos E,
Dimitrakos S, Wilson MR (2005) Risk of sudden visual loss fol-
lowing filtration surgery in end-stage glaucoma. Am J Ophthalmol
140:661–666
17. Kolker AE (1977) Visual prognosis in advanced glaucoma: a com-
parison of medical and surgical therapy for retention of vision in
101 eyes with advanced glaucoma. Trans Am Ophthalmol Soc 75:
539–555
18. Lichter PR (1974) Risks of sudden visual loss after glaucoma sur-
gery. Am J Ophthalmol 78:1009–1013
19. AGIS (Advanced Glaucoma Intervention Study) Investigators
(2001) The Advanced Glaucoma Intervention Study: 8 Risk of
cataract formation after trabeculectomy. Arch Ophthalmol 119:
1771–1779
20. Husain R, Liang S, Foster PJ, Gazzard G, Bunce C, Chew PT, Oen
FT, Khaw PT, Seah SK, Aung T (2012) Cataract surgery after
trabeculectomy: the effect on trabeculectomy function. Arch
Ophthalmol 130:165–170
21. Longo A, Uva MG, Reibaldi A, Avitabile T, Reibaldi M (2015)
Long-term effect of phacoemulsification on trabeculectomy func-
tion. Eye 29:1347–1352
22. Ang GS, Varga Z, Shaarawy T (2010) Postoperative infection in
penetrating versus non-penetrating glaucoma surgery. Br J
Ophthalmol 94:1571–1576
23. Mendrinos E, Mermoud A, Shaarawy T (2008) Nonpenetrating
glaucoma surgery. Surv Ophthalmol 53:592–630
24. Ahmed II, Shaarawy T (2004) Viscocanalostomy versus
trabeculectomy. Ophthalmology 111:1066–1067
25. Tan JC, Hitchings RA (2001) Non-penetrating glaucoma surgery:
the state of play. Br J Ophthalmol 85:234–237
26. Edmunds B, Thompson JR, Salmon JF, Wormald RP (2002) The
National Survey of Trabeculectomy. III Early and late complica-
tions. Eye 16:297–303
27. Law SK, Nguyen AM, Coleman AL (2007) Severe loss of central
vision in patients with advanced glaucoma undergoing
trabeculectomy. Arch Ophthalmol 125:1044–1050
28. Jones NP (1993) Fuchs’ heterochromic uveitis: an update. Surv
Ophthalmol 34:253–272
29. Benedikt O, Roll P, ZirmM (1978) The glaucoma in heterochromic
cyclitis of Fuchs. Gonioscopic studies and electron microscopic
investigations of the trabecular meshwork. Klin Monatsbl
Augenheilkd 173:523–533
30. Traverso CE, Walt JG, Kelly SP et al (2005) Direct costs of glau-
coma and severity of the disease: a multinational long term study of
resource utilisation in Europe. Br J Ophthalmol 89:1245–1249
Graefes Arch Clin Exp Ophthalmol (2018) 256:1481–1487 1487
